scholarly journals Plastic or self‐expandable metal stent: Which is the most suitable for patients with pancreatic head cancer in the upcoming era of neoadjuvant chemotherapy? A review

2021 ◽  
Author(s):  
Sho Hasegawa ◽  
Itaru Endo ◽  
Kensuke Kubota
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Pancreatic Head ◽  
Metal Stent ◽  
Head Cancer ◽  
Pancreatic Head Cancer ◽  
Self Expandable Metal Stent

Su1360 Covered Self-Expandable Metal Stent Deployment Promises Safe Neoadjuvant Chemotherapy in Patients With Borderline Resectable Pancreatic Head Cancer

2012 ◽  
Vol 75 (4) ◽  
pp. AB305-AB306 ◽  
Author(s):  
Kensuke Kubota ◽  
Takamitsu Sato ◽  
Shingo Kato ◽  
Seitaro Watanabe ◽  
Kunihiro Hosono ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Pancreatic Head ◽  
Metal Stent ◽  
Stent Deployment ◽  
Borderline Resectable ◽  
Head Cancer ◽  
Pancreatic Head Cancer ◽  
Self Expandable Metal Stent

Covered self‐expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer

2013 ◽  
Vol 26 (1) ◽  
pp. 77-86 ◽  
Author(s):  
Kensuke Kubota ◽  
Takamitsu Sato ◽  
Seitaro Watanabe ◽  
Kunihiro Hosono ◽  
Noritoshi Kobayashi ◽  
...  
Keyword(s):  
Pancreatic Head ◽  
Neoadjuvant Chemoradiation ◽  
Chemoradiation Therapy ◽  
Metal Stent ◽  
Stent Deployment ◽  
Borderline Resectable ◽  
Head Cancer ◽  
Pancreatic Head Cancer ◽  
Neoadjuvant Chemoradiation Therapy ◽  
Self Expandable Metal Stent

Covered self-expandable metal stent deployment promise safe neoadjubant chemotherapy in patients with borderline resectable pancreatic head cancer

Pancreatology ◽  
2013 ◽  
Vol 13 (2) ◽  
pp. e46
Author(s):  
K. Kubota ◽  
T. Sato ◽  
S. Watanabe ◽  
K. Hosono ◽  
A. Nakajima
Keyword(s):  
Pancreatic Head ◽  
Metal Stent ◽  
Stent Deployment ◽  
Borderline Resectable ◽  
Head Cancer ◽  
Pancreatic Head Cancer ◽  
Self Expandable Metal Stent

scholarly journals Neoadjuvant chemotherapy with gemcitabine‑based regimens improves the prognosis of node positive resectable pancreatic head cancer

2019 ◽  
Author(s):  
Hidehiro Tajima ◽  
Tetsuo Ohta ◽  
Mitsuyoshi Okazaki ◽  
Takahisa Yamaguchi ◽  
Yoshinao Ohbatake ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Pancreatic Head ◽  
Head Cancer ◽  
Pancreatic Head Cancer ◽  
Node Positive

scholarly journals Endosonography-Guided Biliary Drainage with One-Step Placement of a Newly Developed Fully Covered Metal Stent Followed by Duodenal Stenting for Pancreatic Head Cancer

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Kei Ito ◽  
Naotaka Fujita ◽  
Yutaka Noda ◽  
Go Kobayashi ◽  
Takashi Obana ◽  
...  
Keyword(s):  
Biliary Drainage ◽  
Pancreatic Head ◽  
Papilla Of Vater ◽  
Metal Stent ◽  
Invasive Treatment ◽  
Head Cancer ◽  
Pancreatic Head Cancer ◽  
Duodenal Invasion ◽  
One Step ◽  
Pancreatic Head Tumor

An 83-year-old man was admitted to our department, presenting with jaundice, fever, and nausea. CT revealed a pancreatic head tumor with duodenal invasion. Endoscopic transpapillary biliary drainage was unsuccessful due to stenosis at the second portion of the duodenum and tumor invasion to the papilla of Vater. Using a convex linear array echoendoscope, a fully-covered metal stent was placed across the puncture tract to bridge the duodenum and the bile duct. After improvement of jaundice, a duodenal metal stent was placed across the stricture of the duodenum. No procedure-related complications occurred. Neither migration nor obstruction of the two stents was observed during the three months followup period. Combination of ESBD using a fully covered metal stent and duodenal stenting is a feasible technique and possibly a less invasive treatment option for malignant biliary and duodenal obstruction compared to surgery.

Predictors of neoadjuvant chemotherapy efficacy in localized pancreatic head cancer: A 15-year experience at a high volume pancreatic cancer center.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15724-e15724
Author(s):  
Amr I. Al Abbas ◽  
Jacob Hodges ◽  
Patrick Varley ◽  
Connor Buchholz ◽  
Johanna E Bellon ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Cox Regression ◽  
Clinical Stage ◽  
Pancreatic Head ◽  
Vascular Involvement ◽  
Cancer Center ◽  
Head Cancer ◽  
Baseline Serum ◽  
Pancreatic Head Cancer ◽  
Baseline Factors

e15724 Background: Surgery followed by adjuvant chemotherapy (SF) is the standard approach for localized pancreatic adenocarcinoma (PC). Although neoadjuvant chemotherapy (NC) is being increasingly used, its efficacy remains debatable. This study aims to identify baseline factors associated with benefit from NC as compared to SF for PC. Methods: Review of a prospectively maintained database of resected localized head PC undergoing NC or SF at a tertiary referral hospital from 2002 to 2018. Baseline factors investigated included clinical stage by EUS (7th edition AJCC), CT vessel involvement, and serum CA19-9. Baseline CA19-9 levels were grouped into mild (37-200), moderate (200-900), and marked elevations (≥ 900). Patients with baseline serum CA19-9 < 37 IU/dL were excluded from the analysis. Results: In total, 269 patients were evaluated: 165 (61%) received NC and 104 (39%) had SF. Mean patient age was 68.3 years and 50% were females. Of these, 42% had stage IIB, 44% had N1 disease, and 38% had vascular involvement. Compared to SF approach, NC was associated with improved median survival for CA19-9 of < 200 IU/dL (30 vs 21 months, p = 0.08), 200-900 IU/dL (32 vs 17 months, p < 0.01), and the ≥900 IU/dL (33 vs 12 months, p < 0.01) groups. On Cox regression, NC was the only baseline factor predictive of improved survival in the groups with moderate (HR:0.35,[95% CI:0.20-0.62];p < 0.01) and marked (HR:0.36,[95% CI:0.18-0.71];p < 0.01) pretreatment CA19-9 elevation. Notably, NC was not predictive of improved survival in the cohort with mild CA19-9 elevation. Conclusions: This study identifies a cohort of patients that benefits from neoadjuvant chemotherapy over a surgery first approach for localized pancreatic head cancer. Elevation in baseline CA19-9 may serve as the strongest indicator for chemotherapy before resection.

Sign in / Sign up

Export Citation Format

Share Document